In Vitro "Chewing" Studies May Differentiate Abuse-Deterrent Formulations Suggests New Research from DRUGSCAN® and PinneyAssociates

HORSHAM, Pa., Aug. 29, 2017 /PRNewswire/ -- Pharmaceutical companies developing abuse-deterrent formulations may be able to assess a formulation's ability to resist chewing, according to results of an in vitro "chewing" study conducted by DRUGSCAN^© Pharmaceutical Services, leaders in conducting laboratory-based manipulation and extraction studies, and PinneyAssociates, leading experts in the evaluation of abuse-deterrent formulations.  The results will be presented at PAINWeek 2017.

"This in vitro chewing model holds promise for pharmaceutical developers for the creation of safer opioid products that deter common methods of abuse, and potentially support Category 1 oral abuse-deterrent labeling," said Edward Cone, Ph.D., Principal Scientists, Drug Delivery and Abuse-Deterrent Drug Products, PinneyAssociates. "Chewing is one of the most common methods of abusing prescription opioids."

Prescription opioids are abused by various routes of administration, but most commonly via the oral route. Although most abusers start by swallowing an intact pill, some progress to more advanced methods, like chewing, that are intended to circumvent the pills' drug release properties, increasing the speed of opioid release from the tablet and absorption into the body in order to produce a faster and stronger euphoric effect.

Christopher Altomare of DRUGSCAN will present the results at PAINWeek 2017 during the poster session on Thursday, September 7, 6:30pm-8:30pm.

In Vitro Differentiation of Two FDA-Approved Abuse-Deterrent Opioids' Resistance to Oral Mastication

Authors: Christopher Altomare, BS*, James Paletski, BS*, Eric R Kinzler, PhD*, Edward Cone, PhD†, Anthony Costantino, PhD*

*DRUGSCAN, Inc., †Pinney Associates, Inc.

About DRUGSCAN® Inc.

DRUGSCAN's CAT.one® laboratory-based manipulation and extraction studies are designed and conducted to produce data that can predict a product's strengths and weaknesses to physical and chemical manipulations as well as to support abuse-deterrent label claims. Employing state of the art technology and abuse-deterrent testing expertise, DRUGSCAN has been at the forefront of designing and conducting manipulation and extraction studies for many of the leading abuse-deterrent product developers in the US and around the world. To learn more about DRUGSCAN and their CAT.one capabilities, please visit drugscan.com or call 800-235-4890.

About PinneyAssociates, Inc.

PinneyAssociates is a pharmaceutical and consumer healthcare consulting company that helps clients to reduce their regulatory risk and enhance the commercial value of their life sciences products. PinneyAssociates provides services in the areas of abuse-deterrent drug formulation evaluation, abuse potential assessment, and pharmaceutical risk management, as well as Rx-to-OTC switch services and tobacco harm reduction.  Our scientists are leaders in the Category 1 assessment of abuse-deterrent drugs and formulations, including application of our proprietary ALERRT® instrument .  For more information about PinneyAssociates, please visit www.pinneyassociates.com or call +1.301.718.8440.

Media Contact: 
Greg Gironda, DRUGSCAN
800-235-4890

Michelle Ertischek, PinneyAssociates
301-718-8440

SOURCE DRUGSCAN; PinneyAssociates